NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a company "Advancing Drugs Through Glycoscience®", today reported that three of seven (43%) evaluable patients in its Phase II colorectal cancer trial have experienced tumor shrinkage of greater than 30%, a partial response according to Response Evaluation Criteria for Solid Tumors (RECIST). In addition, none of the patients in the trial have experienced hematological or gastrointestinal severe adverse events (SAEs) of grade 3 or higher. SAEs generally result in life threatening events, inpatient hospitalization, persistent or significant disability, or death.
